Using Advanced CT Scans and Blood Markers to Understand Heart Damage and Recovery After a Heart Attack
Official title: SPEctral CT and miRna In Acute Myocardial Infarction for Comprehensive Adverse Remodeling Evaluation
Run by Instituto de Investigación Biomédica de Salamanca · NCT07268391 · Data updated 2026-11-12
Doctors are testing a combination of spectral CT imaging and blood biomarkers to see if they can better understand and predict how the heart heals after a heart attack in adults who recently had STEMI treated with PCI.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 95 (estimated) |
| Sponsor | Instituto de Investigación Biomédica de Salamanca Academic / other |
| Drugs / interventions | radiation |
| Locations | 4 sites (Madrid and 3 other locations) |
| Status | Recruiting |
| Started | September 15, 2025 |
| Main results expected | January 2027 |
| Study ends | December 2028 |
| Registry record updated | August 11, 2026 |
| Trial ID | NCT07268391 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older who had a first STEMI treated with primary PCI and have an LVEF ≤45% during hospitalization.
✕Probably not a fit
Patients without adverse remodeling or those not contributing to predictive models may see limited or no direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study combines spectral CT imaging, blood analysis, and cardiac MRI to examine heart damage and remodeling after a STEMI. It aims to identify imaging and blood-based signals that relate to adverse ventricular remodeling and later heart failure. The approach seeks to provide earlier, more accurate information than standard imaging alone. Participants undergo blood tests, spectral CT scans, and CMR as part of the study protocol to correlate findings with outcomes.
Why it matters
Potential benefit: If successful, the approach could improve early prediction of adverse remodeling and guide personalized treatment to reduce future heart failure risk.
How similar studies have gone: Prior research suggests that combining imaging with biomarkers can improve risk stratification, though this exact spectral CT and miRNA/blood-marker pairing is innovative in post-infarction remodeling.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥18 years. * First STEMI treated with primary PCI. * Left ventricular ejection fraction (LVEF) ≤45% during index hospitalization. * Ability to provide informed consent. Exclusion Criteria: * Contraindication to iodinated contrast media. * Chronic kidney disease with eGFR \<30 mL/min/1.73 m². * Prior myocardial infarction or known cardiomyopathy. * Contraindication to CT or MRI imaging. * Life expectancy \<1 year due to non-cardiac conditions.
Where it's running
-
Hospital La Princesa
Madrid, Spain Recruiting -
Hospital Ramón y Cajal
Madrid, Spain Recruiting -
Complejo Asistencial Universitario de Salamanca
Salamanca, Spain Recruiting -
Hospital Clínico Universitario de Valencia
Valencia, Spain Recruiting
Study contacts
- Study coordinator: Candelas Pérez del Villar, MD in Cardiology
- Email: mcperezvi@saludcastillayleon.es
- Phone: +34923291200
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can 1-Hz rTMS help with heart rhythm and inflammation after a heart attack?
This trial tests whether daily 1-Hz repetitive transcranial magnetic stimulation can improve heart rate variability and reduce inflammation in people who have had an acute myocardial infarction, compared with a sham procedure.
-
Trends and risk factors for adverse events after primary PCI in AMI patients over 20 years
This study looks at real-world AMI patients who had a primary PCI to see how often serious events happen during a 2-year follow-up and what factors predict them.
-
SPIKE FLOW endocardial pacing lead safety and performance study
This study tests whether the SPIKE FLOW temporary endocardial pacing lead is safe and effective in adults needing temporary pacing during heart-related conditions.
-
Predict Arrhythmia Risk with Intelligent Software
Researchers are testing AI-powered predictions to see if clinicians can spot patients at risk for dangerous heart rhythms using bedside ECG data.
-
Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care
In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.
-
BRIDGE: Embedding consumer mHealth tools into cardiac rehab
This study tests whether adding a mobile health tool to standard center-based cardiac rehab helps heart patients stay active and follow healthy habits.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.